Hims & Hers Health is trading 3.6% up at €23.28 as the stock recovers from a sharp decline triggered by regulatory action.
- Shares fell 10.51% to €22.48 on July 29, 2026, after the FTC accused the telehealth firm of misleading consumers and obstructing subscription cancellations.
- The current upward move represents a partial recovery as investors reassess the long-term legal risks relative to the recent price drop.